Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project

Biomedicine and Pharmacotherapy

Volumn 62, Issue 1, 2008, Pages 6-11

  Madeddu, Giordano ^a   Bonfanti, Paolo ^b   De Socio, Giuseppe V ^c   Carradori, Silvia ^d   Grosso, Carmela ^e   Marconi, Patrizia ^f   Penco, Giovanni ^g   Rosella, Elena ^h   Miccolis, Sebastiano ⁱ   Melzi, Sara ^b   Mura, Maria Stella ^a   Landonio, Simona ^b   Ricci, Elena ^b   Quirino, Tiziana ^j   for the CISAI Group, ^k  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Perugia Hospital   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e AUSL Cesena   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h STD Department ASL 3   (Italy)

ⁱ Hospital of Mantova   (Italy)

^j BUSTO ARSIZIO HOSPITAL   (Italy)

^k NONE

more..

Author keywords

HIV; Renal safety; Tenofovir

Indexed keywords

ABACAVIR; ALBUMIN; AMILORIDE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; COTRIMOXAZOLE; CREATININE; DAPSONE; DARUNAVIR; ENFUVIRTIDE; ETACRYNIC ACID; FLUCONAZOLE; LACTULOSE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEGESTROL; METHADONE; OMEPRAZOLE; PENTAMIDINE; PROPRANOLOL; PYRIMETHAMINE; RIFAXIMIN; SPIRONOLACTONE; STAVUDINE; TENOFOVIR; TIPRANAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; ITALY; KIDNEY INJURY; MALE; MORBIDITY; MULTICENTER STUDY; NEPHROTOXICITY; OBSERVATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADENINE; ADULT; AGE FACTORS; ANTI-HIV AGENTS; COHORT STUDIES; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; KIDNEY DISEASES; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 38049006331     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.04.008     Document Type: Article

References (40)

1. Squires K., Pozniak A.L., Pierone Jr. G., Steinhart C.R., Berger D., Bellos N.C., et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 139 (2003) 313-320
2. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
3. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
4. Jones R., Stebbing J., Nelson M., Moyle G., Bower M., Mandalia S., et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 37 (2004) 1489-1495
5. Padilla S., Gutierrez F., Masia M., Canovas V., and Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19 (2005) 421-424
6. Antoniou T., Raboud J.M., Chirhin S., Yoong D., Govan V., Gough K., et al. Incidence and risk factors for tenofovir nephrotoxicity: a retrospective cohort study. HIV Med 6 (2005) 284-290
7. Lanzafame M., Lattuada E., Rapagna F., et al. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals. Clin Infect Dis 42 (2006) 1656 (Letter)
8. Zimmermann A.E., Pizzoferrato T., Bedford J., Gottardi M., and Vento S. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42 (2006) 283-290
9. Crane H, Harrington R, Van Rompaey S, Mikata M. Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir. Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5-8 2006 (abstract 780).
10. Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in first year of therapy. Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5-8 2006 (abstract 778).
11. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences (1996), Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD
12. Bonfanti P., Martinelli C., Ricci E., Carradori S., Parruti G., Armignacco O., et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 39 (2005) 317-320
13. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
14. Gupta S.K., Eustace J.A., Winston J.A., Boydstun I.I., Ahuja T.S., Rodriguez R.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
15. Van Rompay K.K., Brignolo L.L., Meyer D.J., Jerome C., Tarara R., Spinner A., et al. Biological effects of short-term or prolonged administration of 9-[2 (phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48 (2004) 1469-1487
16. Kearney BP, Mittan A, Sayre J, Flaherty JF, Zhong L, Toole JJ, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Program and Abstracts of the 43rd Interscience Conference on Antimicrobials Agents and Chemotherapy; 2003; Chicago (abstract 1617).
17. Cihlar T., Ho E.S., Lin D.C., and Mulato A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20 (2001) 641-648
18. Gutmann H., Fricker G., Drewe J., Toeroek M., and Miller D.S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56 (1999) 383-389
19. Ray A, Vela J, Robinson K, Cihlar T, Rhodes G. Efflux of tenofovir by the multidrug resistance-associated protein 4 (MRp4) is not affected by HIV protease inhibitors. Program and Abstracts of the 10th European AIDS Conference, Dublin, 2005 (abstract PE 4.3/13).
20. Imaoka T., Kusuhara H., Adachi M., Schuetz J.D., Takeuchi K., and Sugiyama Y. Functional involvement of multidrug resistance associated protein 4 (MRP4/ABCC4) in the renal elimination of the anti-viral drugs, adefovir and tenofovir. Mol Pharmacol 71 (2007) 619-627
21. Viread (tenofovir) [package insert]. Foster City, CA: Gilead sciences. October 2001.
22. Crowther M.A., Callaghan W., Hodsman A.B., and Mackie I.D. Dideoxyinosine-associated nephrotoxicity. AIDS 7 (1993) 131-132
23. Metcalfe P.D., and Meldrum K.K. Sex differences and the role of sex steroids in renal injury. J Urol 176 (2006) 15-21
24. West K.M., Endreich L.J., and Stober J.A. A detailed study of risk factors for retinopathy and nephropathy in diabetes. Diabetes 29 (1980) 501-508
25. Held P.J., Port F.K., Blagg C.R., and Agadoa L.Y. The United States Renal Data System's 1990 Annual Data Report: an introduction. Am J Kidney Dis 16 Suppl 2 (1990) 1-106
26. Baylis C. Age-dependent glomerular damage in the rat. Dissociation between glomerulare injury and both glomerula hypertension and hypertrophy. Male gender as primary risk factor. J Clin Invest 94 (1994) 1823-1829
27. Harbart S., Pestotnik S.L., Lloyd J.F., Burke J.P., and Samore M.H. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111 (2001) 528-534
28. Bertino J.S., Booker L.A., Franck P.A., Jenkins K.R., and Nafziger A.N. Incidence of and significant risk factors for aminoglycoside-associated Nephrotoxicity in patients doses by using individualized pharmacokinetic monitoring. J Infect Dis 167 (1993) 173-179
29. Szczech L.A., Gange S.J., van der Horst C., Bartlett J.A., Young M., Cohen M.H., et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 61 (2002) 195-202
30. Heffelfinger J, Hanson D, Voetsch A, McNaghten A, Sullivan P. Renal impairment associated with the use of tenofovir. Program and Abstracts of 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver (abstract 779).
31. Nelson M, Cooper D, Schooley R, Katlama C, Montaner J, Curtis S, et al. The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. Program and Abstracts of 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver (abstract 781).
32. Estrella M., Fine D.M., Gallant J.E., Rahman M.H., Nagajothi N., Racusen L.C., et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 43 (2006) 377-380
33. Daghestani L., and Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 106 (1999) 347-354
34. Sabry A.A., Sobh M.A., Irving W.L., Grabowska A., Wagener B.E., Fox S., et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 17 (2002) 239-245
35. USRDS. 2002 Annual report. Atlas of end stage renal disease in the United States: incidence and prevalence. Am J Kidney Dis 41 (2003) S41-S56
36. Bidani A.K., and Griffin K.A. Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens 11 (2002) 73-80
37. Bidani A.K., and Griffin K.A. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44 (2004) 595-601
38. Viread (tenofovir) [package insert]. Foster City, CA: Gilead sciences, August 2003.
39. Day S.L., Lake Date H.A., Bannister A., Hankins M., and Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Synndr 38 (2005) 301-304
40. Kinai E., and Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alcaline phosphatase levels. AIDS 19 (2005) 2031-2033